Tonix Pharmaceuticals Holding Corp.
TNXPTonix Pharmaceuticals Holding Corp. in brief
Tonix Pharmaceuticals Holding Corp. is a listed company in the Biotechnology industry, based in Berkeley Heights, New Jersey, USA. Its market value was $111 M on 20 October 2026, which makes it the 18,349th largest listed company in the world and the 3,468th largest in the USA on this site. In the year to December 2025 it had sales of $13 M and a net loss of $124 M. Seth Lederman is its chief executive. Its largest product and service lines by sales in 2025 were Zembrace Symtouch (71%), Tosymra (18%) and Tonmya (11%). Its shares trade under the symbol TNXP (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Tonix Pharmaceuticals Holding Corp. timeline
- 2008
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2011
- ✎Renamed Tonix Pharmaceuticals Holding Corp.Formerly Tamandare Explorations Inc..
- 2018
- •Legal Entity Identifier issuedLEI 529900ACPKP9QW20GX48 registered.
- 2025
- 💰Record revenue of $13 millionFY2025, the highest of the 3 years on record.
Events of Tonix Pharmaceuticals Holding Corp. from SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,672 (Jan 2020) · #3,525 (Jan 2021) · #3,997 (Jan 2022) · #5,304 (Dec 2022) · #5,392 (Jul 2023) · #4,324 (Jan 2024) · #1,783 (Mar 2026) · #3,058 (Aug 2026) · #3,398 (Oct 2026) · #3,471 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 8.5×
- Price / book
- 0.5×
- Free cash flow yield
- -92.7%
- Net margin
- -946.0%
- Operating margin
- -958.8%
- Return on equity
- -50.6%
- Liabilities / assets
- 11.6%
- Net debt
- $-90M
- Revenue growth
- +29.9%
- R&D / revenue
- 339.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $13M | +29.9% | $-126M | $-124M | -946.0% |
| Dec 2024 | $10M | +29.9% | $-137M | $-130M | -1288.8% |
| Dec 2023 | $8M | — | $-118M | $-117M | -1501.4% |
| Dec 2022 | — | — | $-112M | $-110M | — |
| Dec 2021 | — | — | $-92M | $-92M | — |
| Dec 2020 | — | — | $-51M | $-50M | — |
| Dec 2019 | — | — | $-29M | $-29M | — |
| Dec 2018 | — | — | $-26M | $-26M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-100M | $3M | $-103M | $-14.57 | — |
| Dec 2024 | $-61M | $0M | $-61M | $-176.60 | — |
| Dec 2023 | $-102M | $8M | $-110M | $-14720.25 | — |
| Dec 2022 | $-98M | $48M | $-146M | $-20.01 | — |
| Dec 2021 | $-76M | $35M | $-111M | $-8.10 | — |
| Dec 2020 | $-49M | $9M | $-57M | $-0.55 | — |
| Dec 2019 | $-27M | $0M | $-27M | $-19.33 | — |
| Dec 2018 | $-24M | $0M | $-24M | $-259.85 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $17M (+423.7% on a year earlier), net income $-53M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Oct 15, 20268-KCurrent reportResults of operations · Other events
- Oct 2, 20268-KCurrent reportOther events
- Sep 22, 20268-KCurrent reportOther events
- Sep 8, 20268-KCurrent reportOther events
- Aug 18, 20268-KCurrent reportDirectors or officers changed · Other events
- Aug 10, 202610-QQuarterly report · period to Jun 2026
- Aug 10, 20268-KCurrent reportResults of operations
- Aug 3, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jul 21, 20268-KCurrent reportDirectors or officers changed
- Jul 13, 20268-KCurrent reportRegulation FD disclosure · Other events
Official filings of Tonix Pharmaceuticals Holding Corp. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $13 M
- Operating income
- $-126 M
- Net income
- $-124 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $277 M
- Total liabilities
- $32 M
- Total equity
- $245 M
As of December-2025
Top 100 institutional investors in Tonix Pharmaceuticals Holding Corp.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1,563,129 | +165,088 (+11.81%) | 8.04% | $15 M | Nov 13, 2026 |
| 2 | Point72 Asset Management, L.P. | 1,116,449 | -50,303 (-4.31%) | 5.75% | $11 M | Nov 16, 2026 |
| 3 | Millennium Management LLC | 818,779 | -148,153 (-15.32%) | 4.21% | $8 M | Nov 16, 2026 |
| 4 | Vanguard Capital Management LLC | 691,895 | 0 (0.00%) | 3.56% | $7 M | Nov 13, 2026 |
| 5 | AQR Capital Management LLC | 670,805 | -211,790 (-24.00%) | 3.45% | $7 M | Nov 16, 2026 |
| 6 | Jones Hill Capital LP | 563,739 | -61,689 (-9.86%) | 2.90% | $5 M | Nov 13, 2026 |
| 7 | Logos Global Management LP | 550,000 | New | 2.83% | $5 M | Nov 16, 2026 |
| 8 | Geode Capital Management, LLC | 425,177 | +29,917 (+7.57%) | 2.19% | $4 M | Nov 6, 2026 |
| 9 | Citadel Advisors LLC | 337,434 | +141,575 (+72.28%) | 1.74% | $3 M | Nov 16, 2026 |
| 10 | State Street Corp | 335,083 | +63,709 (+23.48%) | 1.72% | $3 M | Nov 12, 2026 |
| 11 | Essex Investment Management Co LLC | 292,397 | +127,253 (+77.06%) | 1.50% | $3 M | Oct 19, 2026 |
| 12 | Trexquant Investment LP | 263,591 | +199,956 (+314.22%) | 1.36% | $3 M | Nov 16, 2026 |
| 13 | FMR LLC | 231,852 | +138,301 (+147.83%) | 1.19% | $2 M | Nov 10, 2026 |
| 14 | UBS Group AG | 153,026 | -78,656 (-33.95%) | 0.79% | $1 M | Nov 10, 2026 |
| 15 | Northern Trust Corp | 128,474 | +8,088 (+6.72%) | 0.66% | $1 M | Nov 16, 2026 |
| 16 | Nuveen, LLC | 118,761 | +1,314 (+1.12%) | 0.61% | $1 M | Nov 10, 2026 |
| 17 | Vanguard Fiduciary Trust Co | 118,107 | +16,053 (+15.73%) | 0.61% | $1 M | Nov 13, 2026 |
| 18 | Vanguard Portfolio Management LLC | 112,171 | +14,217 (+14.51%) | 0.58% | $1 M | Nov 13, 2026 |
| 19 | Goldman Sachs Group Inc | 104,487 | +6,131 (+6.23%) | 0.54% | $1 M | Nov 16, 2026 |
| 20 | Susquehanna Portfolio Strategies, LLC | 101,161 | +36,137 (+55.57%) | 0.52% | $1 M | Nov 16, 2026 |
| 21 | Legato Capital Management LLC | 90,340 | +34,720 (+62.42%) | 0.46% | $1 M | Nov 10, 2026 |
| 22 | Man Group plc | 80,374 | +61,705 (+330.52%) | 0.41% | $1 M | Nov 16, 2026 |
| 23 | Superstring Capital Management LP | 74,688 | +11,040 (+17.35%) | 0.38% | $1 M | Nov 16, 2026 |
| 24 | Panagora Asset Management Inc | 69,771 | +13,065 (+23.04%) | 0.36% | $1 M | Nov 12, 2026 |
| 25 | Jacobs Levy Equity Management, Inc | 67,213 | +9,270 (+16.00%) | 0.35% | $1 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Ieq Capital, LLC | 61,595 | -30,778 (-33.32%) | 0.32% | $1 M | Nov 10, 2026 |
| 27 | SEI Investments Co | 57,360 | +20,888 (+57.27%) | 0.30% | $1 M | Nov 10, 2026 |
| 28 | Charles Schwab Investment Management Inc | 56,454 | +3,841 (+7.30%) | 0.29% | $1 M | Nov 16, 2026 |
| 29 | Invesco Ltd. | 51,039 | +13,348 (+35.41%) | 0.26% | $0 M | Nov 12, 2026 |
| 30 | Bridgeway Capital Management, LLC | 44,673 | +24,673 (+123.36%) | 0.23% | $0 M | Nov 16, 2026 |
| 31 | Bank of New York Mellon Corp | 41,732 | -22 (-0.05%) | 0.21% | $0 M | Nov 5, 2026 |
| 32 | Los Angeles Capital Management LLC | 40,216 | +40,140 (+52815.79%) | 0.21% | $0 M | Nov 12, 2026 |
| 33 | D. E. Shaw & Co., Inc. | 35,294 | New | 0.18% | $0 M | Nov 16, 2026 |
| 34 | Two Sigma Investments, LP | 31,153 | +2,341 (+8.13%) | 0.16% | $0 M | Nov 16, 2026 |
| 35 | Jain Global LLC | 25,902 | New | 0.13% | $0 M | Nov 16, 2026 |
| 36 | Bank Of America Corp /de/ | 25,674 | -35,303 (-57.90%) | 0.13% | $0 M | Nov 16, 2026 |
| 37 | Morgan Stanley | 24,782 | +9,541 (+62.60%) | 0.13% | $0 M | Nov 13, 2026 |
| 38 | Alliancebernstein L.P. | 24,030 | 0 (0.00%) | 0.12% | $0 M | Nov 16, 2026 |
| 39 | Balyasny Asset Management L.P. | 23,819 | -108,772 (-82.04%) | 0.12% | $0 M | Nov 16, 2026 |
| 40 | Squarepoint Ops LLC | 21,530 | New | 0.11% | $0 M | Nov 9, 2026 |
| 41 | Empowered Funds, LLC | 19,673 | New | 0.10% | $0 M | Nov 13, 2026 |
| 42 | Mariner, LLC | 19,393 | -22,377 (-53.57%) | 0.10% | $0 M | Nov 12, 2026 |
| 43 | Price T Rowe Associates Inc /MD/ | 19,363 | 0 (0.00%) | 0.10% | $0 M | Nov 16, 2026 |
| 44 | Rhumbline Advisers | 18,390 | +956 (+5.48%) | 0.09% | $0 M | Nov 10, 2026 |
| 45 | Cerity Partners LLC | 18,251 | -12,823 (-41.27%) | 0.09% | $0 M | Nov 13, 2026 |
| 46 | Acadian Asset Management LLC | 15,311 | New | 0.08% | $0 M | Nov 9, 2026 |
| 47 | American Century Companies Inc | 15,258 | 0 (0.00%) | 0.08% | $0 M | Nov 12, 2026 |
| 48 | Raymond James Financial Inc | 15,207 | New | 0.08% | $0 M | Nov 12, 2026 |
| 49 | Dimensional Fund Advisors LP | 14,521 | 0 (0.00%) | 0.07% | $0 M | Nov 4, 2026 |
| 50 | Virtu Financial LLC | 13,796 | New | 0.07% | $0 M | Nov 17, 2026 |
| 51 | Deutsche Bank AG\ | 13,771 | +1,223 (+9.75%) | 0.07% | $0 M | Nov 6, 2026 |
| 52 | Arax Advisory Partners | 13,656 | -3,742 (-21.51%) | 0.07% | $0 M | Nov 12, 2026 |
| 53 | Mercer Global Advisors Inc /adv | 13,499 | -10,319 (-43.32%) | 0.07% | $0 M | Nov 16, 2026 |
| 54 | Prudential Financial Inc | 13,405 | New | 0.07% | $0 M | Nov 16, 2026 |
| 55 | Susquehanna Fundamental Investments, LLC | 13,200 | New | 0.07% | $0 M | Nov 16, 2026 |
| 56 | Bolton Securities Corporation | 13,000 | 0 (0.00%) | 0.07% | $0 M | Nov 12, 2026 |
| 57 | Acorn Wealth Advisors, LLC | 13,000 | New | 0.07% | $0 M | Oct 19, 2026 |
| 58 | Wealth Enhancement Advisory Services, LLC | 12,613 | -11,066 (-46.73%) | 0.06% | $0 M | Oct 13, 2026 |
| 59 | Savant Capital, LLC | 12,186 | New | 0.06% | $0 M | Nov 6, 2026 |
| 60 | Axq Capital, LP | 12,090 | New | 0.06% | $0 M | Nov 12, 2026 |
| 61 | Canada Pension Plan Investment Board | 11,500 | New | 0.06% | $0 M | Nov 16, 2026 |
| 62 | Barclays PLC | 10,472 | +3,126 (+42.55%) | 0.05% | $0 M | Nov 6, 2026 |
| 63 | Larson Financial Group LLC | 9,700 | -25 (-0.26%) | 0.05% | $0 M | Nov 5, 2026 |
| 64 | MetLife Investment Management, LLC | 9,119 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 65 | Russell Investments Group, Ltd. | 8,944 | +1,025 (+12.94%) | 0.05% | $0 M | Nov 6, 2026 |
| 66 | Jpmorgan Chase & Co | 8,775 | +2,664 (+43.59%) | 0.05% | $0 M | Nov 12, 2026 |
| 67 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 7,832 | +1,141 (+17.05%) | 0.04% | $0 M | Nov 16, 2026 |
| 68 | Vanguard Global Advisers, LLC | 7,323 | +2,594 (+54.85%) | 0.04% | $0 M | Nov 13, 2026 |
| 69 | Wells Fargo & Company/mn | 6,408 | -9,010 (-58.44%) | 0.03% | $0 M | Nov 16, 2026 |
| 70 | BNP Paribas Financial Markets | 5,948 | +3,976 (+201.62%) | 0.03% | $0 M | Nov 12, 2026 |
| 71 | Police & Firemen's Retirement System of New Jersey | 4,911 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 72 | Tower Research Capital LLC (TRC) | 4,813 | +4,524 (+1565.40%) | 0.02% | $0 M | Nov 16, 2026 |
| 73 | Steward Partners Investment Advisory, LLC | 4,000 | New | 0.02% | $0 M | Nov 13, 2026 |
| 74 | Cornerstone National Bank & Trust Co | 3,330 | 0 (0.00%) | 0.02% | $0 M | Oct 20, 2026 |
| 75 | New York State Common Retirement Fund | 2,900 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 76 | Global Retirement Partners, LLC | 2,893 | New | 0.01% | $0 M | Nov 10, 2026 |
| 77 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,173 | +2,032 (+1441.13%) | 0.01% | $0 M | Nov 16, 2026 |
| 78 | Nisa Investment Advisors, LLC | 2,125 | -2,817 (-57.00%) | 0.01% | $0 M | Oct 20, 2026 |
| 79 | Legal & General Group Plc | 1,470 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 80 | Ameritas Investment Partners, Inc. | 1,459 | +686 (+88.75%) | 0.01% | $0 M | Nov 13, 2026 |
| 81 | Strs Ohio | 1,100 | New | 0.01% | $0 M | Oct 30, 2026 |
| 82 | Rockefeller Capital Management L.P. | 870 | +500 (+135.14%) | 0.00% | $0 M | Nov 13, 2026 |
| 83 | Royal Bank Of Canada | 851 | -10 (-1.16%) | 0.00% | $0 M | Nov 16, 2026 |
| 84 | Allworth Financial LP | 825 | -228 (-21.65%) | 0.00% | $0 M | Nov 17, 2026 |
| 85 | Citigroup Inc | 800 | -5,927 (-88.11%) | 0.00% | $0 M | Nov 4, 2026 |
| 86 | IFP Advisors, Inc | 796 | -653 (-45.07%) | 0.00% | $0 M | Oct 16, 2026 |
| 87 | PNC Financial Services Group, Inc. | 741 | +573 (+341.07%) | 0.00% | $0 M | Nov 6, 2026 |
| 88 | Essential Partners LLC | 693 | -409 (-37.11%) | 0.00% | $0 M | Oct 14, 2026 |
| 89 | EverSource Wealth Advisors, LLC | 623 | -550 (-46.89%) | 0.00% | $0 M | Nov 4, 2026 |
| 90 | Osaic Holdings, Inc. | 620 | -1,547 (-71.39%) | 0.00% | $0 M | Nov 12, 2026 |
| 91 | Farther Finance Advisors, LLC | 574 | +272 (+90.07%) | 0.00% | $0 M | Oct 8, 2026 |
| 92 | Gen-Wealth Partners Inc | 533 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 93 | Optiver Holding B.V. | 518 | New | 0.00% | $0 M | Nov 16, 2026 |
| 94 | SJS Investment Consulting Inc. | 484 | -9,720 (-95.26%) | 0.00% | $0 M | Oct 26, 2026 |
| 95 | Sterling Capital Management LLC | 319 | +25 (+8.50%) | 0.00% | $0 M | Oct 22, 2026 |
| 96 | GAMMA Investing LLC | 252 | -36 (-12.50%) | 0.00% | $0 M | Oct 8, 2026 |
| 97 | California State Teachers Retirement System | 191 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 98 | MassMutual Private Wealth & Trust, FSB | 160 | 0 (0.00%) | 0.00% | $0 M | Oct 5, 2026 |
| 99 | Rothschild Investment LLC | 146 | -153 (-51.17%) | 0.00% | $0 M | Nov 10, 2026 |
| 100 | Root Financial Partners, LLC | 137 | New | 0.00% | $0 M | Oct 21, 2026 |
Mutual funds holding Tonix Pharmaceuticals Holding Corp.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 488,108 | $6 M | 2.5% | <0.01% | +36% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 389,931 | $5 M | 2.0% | <0.01% | +18% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 187,414 | $2 M | 0.96% | <0.01% | +28% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 145,820 | $2 M | 0.75% | 0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 158,829 | $2 M | 0.82% | <0.01% | +18% | Jul 31, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 78,342 | $1 M | 0.40% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 69,338 | $1 M | 0.36% | <0.01% | +21% | May 31, 2026 |
| 🇺🇸 1290 Essex Small Cap Growth FundEquitable Investment Management, LLC | 73,840 | $1 M | 0.38% | 0.64% | new | Jul 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 54,920 | $1 M | 0.28% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 49,085 | $1 M | 0.25% | 0.04% | +43% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 35,565 | $0 M | 0.18% | <0.01% | −43% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 29,354 | $0 M | 0.15% | <0.01% | +49% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 36,301 | $0 M | 0.19% | <0.01% | +22% | Jul 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 31,079 | $0 M | 0.16% | <0.01% | −55% | Jul 31, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 22,648 | $0 M | 0.12% | 0.08% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 21,661 | $0 M | 0.11% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 20,358 | $0 M | 0.10% | 0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 20,000 | $0 M | 0.10% | 0.17% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 19,343 | $0 M | 0.10% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 17,997 | $0 M | 0.09% | <0.01% | +3.1% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 17,892 | $0 M | 0.09% | <0.01% | +46% | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 21,611 | $0 M | 0.11% | <0.01% | +100% | Jul 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 19,503 | $0 M | 0.10% | <0.01% | +38% | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 13,190 | $0 M | 0.07% | <0.01% | +71% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 16,263 | $0 M | 0.08% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 12,850 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC | 11,508 | $0 M | 0.06% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 10,840 | $0 M | 0.06% | <0.01% | +102% | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 10,495 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 10,431 | $0 M | 0.05% | 0.01% | +23% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 8,566 | $0 M | 0.04% | <0.01% | +106% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 8,521 | $0 M | 0.04% | <0.01% | +239% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 7,807 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 7,701 | $0 M | 0.04% | <0.01% | +7.8% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 7,600 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 7,400 | $0 M | 0.04% | <0.01% | +37% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 7,600 | $0 M | 0.04% | <0.01% | +15% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 9,314 | $0 M | 0.05% | <0.01% | +41% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 6,590 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 6,334 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 5,930 | $0 M | 0.03% | <0.01% | +40% | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 6,926 | $0 M | 0.04% | <0.01% | +16% | Jul 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 6,874 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 4,995 | $0 M | 0.03% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 6,070 | $0 M | 0.03% | <0.01% | +37% | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 4,700 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 4,993 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 3,624 | $0 M | 0.02% | <0.01% | +47% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,589 | $0 M | 0.02% | <0.01% | +48% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 3,317 | $0 M | 0.02% | 0.02% | +37% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 3,255 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 3,016 | $0 M | 0.02% | <0.01% | +22% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC | 2,699 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 2,356 | $0 M | 0.01% | <0.01% | +22% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 2,199 | $0 M | 0.01% | <0.01% | +43% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 2,106 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 2,053 | $0 M | 0.01% | <0.01% | +41% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 2,610 | $0 M | 0.01% | <0.01% | +30% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 1,557 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 1,970 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,838 | $0 M | <0.01% | <0.01% | +26% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 1,708 | $0 M | <0.01% | <0.01% | +76% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 1,270 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 1,163 | $0 M | <0.01% | <0.01% | +57% | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 1,442 | $0 M | <0.01% | <0.01% | +807% | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 1,093 | $0 M | <0.01% | <0.01% | +24% | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 1,076 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 1,100 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC | 974 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 1,193 | $0 M | <0.01% | <0.01% | +137% | Jul 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 927 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 899 | $0 M | <0.01% | <0.01% | +73% | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,061 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 1,037 | $0 M | <0.01% | <0.01% | −13% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 773 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 726 | $0 M | <0.01% | <0.01% | +169% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 684 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 639 | $0 M | <0.01% | <0.01% | +27% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 500 | $0 M | <0.01% | <0.01% | −31% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 506 | $0 M | <0.01% | <0.01% | −29% | May 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 315 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 300 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 244 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 215 | $0 M | <0.01% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 108 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Wilshire 5000 Index FundWilshire Advisors LLC | 76 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 77 | $0 M | <0.01% | <0.01% | +6.9% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 87 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Tonix Pharmaceuticals Holding Corp.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Seth LedermanChief Executive Officer, Director | Buy | +5,000 | $4.055 | $20 K | 16,005 | Form 4 |
| filed | Seth LedermanChief Executive Officer, Director | Buyindirect | +2,000 | $13.79 | $28 K | 11,005 | Form 4 |
| filed | Richard H. BaggerDirector | Buy | +1,000 | $12.60 | $13 K | 1,000 | Form 4 |
| filed | Bradley SaengerChief Financial Officer | Other | +1,453 | $10.91 | $16 K | 2,154 | Form 4 |
| filed | Carolyn E. TaylorDirector | Buy | +1,415 | $10.55 | $15 K | 1,833 | Form 4 |
| filed | Seth LedermanChief Executive Officer, Director | Buy | +5,000 | $11.79 | $59 K | 9,005 | Form 4 |
| filed | Richard Newcomb StillwellDirector | Buy | +5,000 | $11.65 | $58 K | 5,000 | Form 4 |
| filed | Seth LedermanChief Executive Officer, Director | Buyindirect | +5,000 | $12.62 | $63 K | 20,001 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Tonix Pharmaceuticals Holding Corp.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split ; 1-for-10 reverse split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2025 | Q4 2025 | $7.8M |
| Q3 2025 | Q3 2025 | $0M |
| Q2 2025 | Q2 2025 | $2.9M |
| Q1 2025 | Q1 2025 | $3M |
| Q4 2023 | Q4 2023 | $0M |
| Q3 2023 | Q3 2023 | $0M |
| Q2 2023 | Q2 2023 | $0M |
| Q1 2023 | Q1 2023 | $14M |
Trading halts
- 2025-08-18 13:33 UTC, code LUDP, resumed 13:38 UTC
- 2025-08-15 17:03 UTC, code T3, resumed 20:15 UTC
- 2025-02-05 00:50 UTC, code T3, resumed 14:00 UTC
- 2024-12-17 14:47 UTC, code LUDP, resumed 14:52 UTC
- 2024-12-17 14:40 UTC, code LUDP, resumed 14:45 UTC
Fails to deliver
- : 27,371 shares at $5.73
- : 7 shares at $6.04
- : 24,282 shares at $6.13
- : 2,201 shares at $7.55
- : 8,285 shares at $9.23
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Tonix Pharmaceuticals Holding Corp. scorecard#
Passes 5 of the 17 checks that could be worked out: strongest in valuation (2 of 5), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 20, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.5×Price to book 0.5× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median8.5×Price to sales 8.5× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-92.7%Free cash flow is -92.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 3
- ✓Revenue grew in the newest year29.9%Revenue up 29.9% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-14.57 vs -176.60Diluted EPS -14.57 in fiscal 2025 against -176.60 the year before (report's currency).
- ✗Net income higher than five years earlier-$124 M-$124 M in fiscal 2025 against -$50 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$124 MNet income -$124 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-958.8%-958.8% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-64.5%-64.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities7.4×Current ratio 7.42 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-2.82Z-score -2.82 (distress zone) for fiscal 2025.
Shareholder returns1 of 2
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- ✓Dividends and buybacks above 3% of the market value12.4%Dividends and buybacks were 12.4% of the market value.
- ✗Free cash flow covers dividends and buybacks-$103 MFree cash flow -$103 M against $14 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Tonix Pharmaceuticals Holding Corp.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -958.8% | -60.5% | |
| Net margin | -946.0% | -68.9% | |
| Return on equity | -64.5% | -61.0% | |
| Revenue growth | 29.9% | 15.8% | |
| Free cash flow margin | -787.3% | -61.5% |
4of 8on the Piotroski tests of financial strength
- Net loss of $124 million, the 16th loss-making year in a row.
- Free cash flow was negative: -$103 million.
- Receivables grew 70% while revenue grew 30%: customers are paying later, or sales were booked ahead of cash.
Tonix Pharmaceuticals Holding Corp.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 13+29.8%100% | 10+29.9%100% | 7.8—100% | — | — | — | — | — | — | — | |
| Cost of revenue | 6.6−14.5%50.7% | 7.8+63.8%76.9% | 4.7—61.0% | — | — | — | — | — | — | — | |
| Research and development | 44+11.3%339% | 40−53.9%396% | 87+5.8%1116% | 82+18.9%— | 69+90.4%— | 36+98.8%— | 18+3.6%— | 18+31.6%— | 13−53.2%— | 29—— | |
| Selling, general and administrative | 88+119%669% | 40+15.4%397% | 35+15.0%447% | 30—— | — | — | — | — | — | — | |
| General and administrative | — | — | — | 30+28.7%— | 23+63.5%— | 14+35.0%— | 11+21.4%— | 8.8+10.3%— | 7.9−23.8%— | 10—— | |
| Total costs and expenses | 139−5.4%1059% | 147+16.4%1454% | 126+12.5%1624% | 112+21.4%— | 92+82.8%— | 51+75.2%— | 29+9.5%— | 26+23.6%— | 21−45.4%— | 39—— | |
| Operating income | −126—−959% | −137—−1354% | −118—−1524% | −112—— | −92—— | −51—— | −29—— | −26—— | −21—— | −39—— | |
| Interest and finance income | 4.1+18745%31.6% | 0.0−98.7%0.2% | 1.7−8.1%22.2% | 1.9+7392%— | 0.0−47.9%— | 0.0−77.1%— | 0.2−9.9%— | 0.2+38.7%— | 0.2+32.3%— | 0.1—— | |
| Interest expense and finance costs | 0.1−92.8%0.7% | 1.2—12.2% | — | — | — | — | — | — | — | — | |
| Provision for credit losses | 0.0—0.2% | — | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | −3.3—−25.1% | −0.9r−2.1−150%−8.6% | 1.7—22.2% | — | — | — | — | — | — | — | |
| Income before tax | — | — | — | — | — | — | — | — | −21—— | −39—— | |
| Net income attributable to shareholders | −124—−946% | −130—−1288% | −117—−1502% | −110—— | −92—— | −50—— | −29—— | −26—— | −21—— | −39—— | |
| Earnings per share, basic | -14.57—— | -176.60—— | -14,720.25r-6.85—— | -20.01r-3.27—— | -8.10r-0.26—— | -0.55—— | -19.33—— | -259.85r-26.81—— | -31.69r-3.17—— | -15.41—— | |
| Earnings per share, diluted | -14.57—— | -176.60—— | -14,720.25r-6.85—— | -20.01r-3.27—— | -8.10r-0.26—— | -0.55—— | -19.33—— | -259.85r-26.81—— | -31.69r-3.17—— | -15.41—— | |
| Shares, weighted average (basic) | 8.5+1056%— | 0.7+9191%— | 0.0r17−99.9%— | 5.8r36−48.7%— | 11—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 8.5+1056%— | 0.7+9191%— | 0.0r17−99.9%— | 5.8r36−48.7%— | 11r360−88.0%— | 95+5780%— | 1.6+1324%— | 0.1r1.1−83.1%— | 0.7r6.7−73.6%— | 2.5—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 208+110%74.9% | 99+296%60.6% | 25−79.2%16.2% | 120−32.7%53.3% | 179+132%74.2% | 77+585%78.5% | 11−55.1%77.3% | 25−1.8%95.1% | 25+34.6%95.3% | 19—68.9% | |
| Receivables | 6.3+70.3%2.3% | 3.7—2.3% | — | — | — | — | — | — | — | — | |
| Inventory | — | 8.4−38.4%5.2% | 14—8.8% | — | — | — | — | — | — | — | |
| Other current assets | 9.0+10.1%3.2% | 8.1+265%5.0% | 2.2−78.9%1.4% | 11+1.5%4.7% | 10−4.9%4.3% | 11+305%11.1% | 2.7+164%18.5% | 1.0+7.9%3.9% | 0.9−7.1%3.5% | 1.0—3.7% | |
| Current assets | 229+92.3%82.6% | 119+149%73.1% | 48−63.5%30.9% | 131−30.8%57.9% | 189+115%78.5% | 88+531%89.6% | 14−46.5%95.8% | 26−1.5%99.0% | 26−2.6%98.8% | 27—98.7% | |
| Property, plant and equipment | 44+5.2%16.0% | 42−55.1%25.9% | 94+0.2%60.9% | 94+85.6%41.6% | 51+490%21.0% | 8.6+25109%8.7% | 0.0−20.9%0.2% | 0.0−52.7%0.2% | 0.1−39.3%0.3% | 0.2—0.5% | |
| Right-of-use (leased) assets | 1.5+173%0.6% | 0.6−31.4%0.3% | 0.8+15.2%0.5% | 0.7−21.8%0.3% | 0.9−27.3%0.4% | 1.3+253%1.3% | 0.4—2.4% | — | — | — | |
| Goodwill | — | — | 1.0—0.6% | — | — | — | — | — | — | — | |
| Other intangible assets | 0.10.0%0.0% | 0.1−98.8%0.1% | 9.7+8019%6.3% | 0.10.0%0.1% | 0.10.0%0.0% | 0.10.0%0.1% | 0.10.0%0.8% | 0.10.0%0.5% | 0.10.0%0.4% | 0.1—0.4% | |
| Total assets | 277+70.2%100% | 163+5.5%100% | 154−31.6%100% | 226−6.3%100% | 241+145%100% | 98+574%100% | 15−44.7%100% | 26−1.6%100% | 27−2.7%100% | 28—100% | |
| Accounts payable | 8.1+78.5%2.9% | 4.5+20.2%2.8% | 3.8−53.1%2.4% | 8.1−39.3%3.6% | 13+189%5.5% | 4.6+49.8%4.7% | 3.1+119%21.1% | 1.4+8.3%5.3% | 1.3+48.6%4.8% | 0.9—3.2% | |
| Debt due within a year | — | 2.8+20.0%1.7% | 2.4—1.5% | — | — | — | — | — | — | — | |
| Current liabilities | 31+68.4%11.1% | 18−3.1%11.2% | 19+3.9%12.2% | 18−16.3%8.1% | 22+121%9.0% | 9.8+91.2%10.0% | 5.1+93.4%35.3% | 2.7+24.9%10.1% | 2.1+0.5%7.9% | 2.1—7.7% | |
| Long-term debt | — | 4.7−28.9%2.9% | 6.6—4.2% | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 1.2+231%0.4% | 0.4−43.4%0.2% | 0.6+92.7%0.4% | 0.3−29.8%0.1% | 0.5−34.8%0.2% | 0.7+11833%0.7% | 0.0—0.0% | — | — | — | |
| Total liabilities | 32+37.2%11.6% | 23−52.3%14.3% | 49+164%31.7% | 19−16.6%8.2% | 22+111%9.2% | 11+105%10.7% | 5.1+93.6%35.3% | 2.7+24.2%10.1% | 2.1−0.5%8.0% | 2.1—7.8% | |
| Retained earnings | −855—−308% | −731—−449% | −601—−389% | −470—−208% | −360—−149% | −268—−272% | −217—−1491% | −188—−716% | −162—−607% | −141—−513% | |
| Shareholders' equity | 245+75.7%88.4% | 140+32.3%85.7% | 106−49.1%68.3% | 207−5.3%91.8% | 219+150%90.8% | 88+831%89.3% | 9.4−60.2%64.7% | 24−3.9%89.9% | 25−2.9%92.0% | 25—92.2% | |
| Total liabilities and equity | 277+70.2%100% | 163+5.5%100% | 154−31.6%100% | 226−6.3%100% | 241+145%100% | 98+574%100% | 15−44.7%100% | 26−1.6%100% | 27−2.7%100% | 28—100% | |
| Shares outstanding | 13+192%— | 4.4+20859%— | 0.0r59−99.8%— | 12r76−20.9%— | 16r496−92.4%— | 206+2315%— | 8.5+2496%— | 0.3r3.3−58.2%— | 0.8r7.8−79.9%— | 3.9r3.9—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.9−43.7%14.7% | 3.4−20.3%33.9% | 4.3+242%55.2% | 1.3+2406%— | 0.1+85.2%— | 0.0+3.8%— | 0.0−51.9%— | 0.1−22.9%— | 0.1−66.0%— | 0.2—— | |
| Share-based compensation | 6.0+25.9%45.9% | 4.8−48.5%47.3% | 9.3−15.0%119% | 11+38.2%— | 7.9+175%— | 2.9+97.4%— | 1.5−10.4%— | 1.6−9.1%— | 1.8−45.2%— | 3.3—— | |
| Cash from operating activities | −100—−762% | −61—−604% | −102—−1313% | −98—— | −76—— | −49—— | −27—— | −24—— | −19—— | −37r−37—— | |
| Capital expenditure | −3.4—−25.7% | −0.1—−1.2% | −7.9—−102% | −48—— | −35—— | −8.6—— | −0.0—— | −0.0—— | −0.0—— | −0.1—— | |
| Cash from investing activities | −4.5—−34.5% | −0.1—−1.2% | −29—−374% | −48—— | −35—— | −8.6—— | −0.0—— | −0.0−100%— | 7.2−56.7%— | 17r17—— | |
| Debt repaid | −9.7—−73.6% | −2.4—−23.3% | — | — | — | — | — | — | — | — | |
| Shares issued | 238+69.7%1815% | 140+640%1389% | 19−80.0%244% | 94−55.5%— | 212+95.6%— | 109+1760%— | 5.8r5.9−54.1%— | 13−31.3%— | 19−9.7%— | 20—— | |
| Shares bought back | −14—−105% | — | −14—−180% | — | — | — | — | — | — | — | |
| Cash from financing activities | 215+59.1%1637% | 135+269%1336% | 37−58.4%470% | 88−58.7%— | 212+72.6%— | 123+853%— | 13−45.1%— | 24+27.1%— | 19−9.7%— | 20—— | |
| Exchange-rate effect on cash | −0.0−875%−0.2% | 0.0—0.0% | −0.1—−0.8% | −0.1—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | — | — | |
| Change in cash | 110+49.2%840% | 74—731% | −95—−1218% | −58−158%— | 102+54.0%— | 66—— | −14—— | −0.5−107%— | 6.6—— | −0.3r−0.2—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 43+318%100% | 17+424%100% | 14+578%100% | 6.9+183%100% | 5.4*+109%100% | 3.3+16.6%100% | 2.0−9.5%100% | 2.4−2.1%100% | 2.6*−31.7%100% | 2.8—100% | 2.2—100% | 2.5—100% | 3.8*—100% | |
| Cost of revenue | 4.6−32.1%10.7% | 1.3−8.4%7.3% | 0.7−78.5%5.2% | 1.6+67.3%22.9% | 1.1*−10.6%19.6% | 1.4−12.1%41.6% | 3.3−2.8%164% | 0.9−43.2%38.8% | 1.2*−50.0%45.8% | 1.6—55.1% | 3.4—152% | 1.7—66.9% | 2.4*—62.6% | |
| Research and development | 80+124%187% | 26+178%150% | 19+79.5%143% | 18+145%265% | 17*+104%314% | 9.3+1.9%282% | 11+11.6%542% | 7.4−42.2%306% | 8.3*−51.5%321% | 9.1—323% | 9.7—439% | 13—518% | 17*—453% | |
| Selling, general and administrative | 146+116%339% | 46+77.4%265% | 36+122%265% | 29+183%416% | 36*+129%662% | 26+233%781% | 16+116%811% | 10+8.5%416% | 16*+34.1%603% | 7.7—273% | 7.5—340% | 9.3—375% | 12*—308% | |
| Total costs and expenses | 231+109%536% | 73+99.9%422% | 56+85.1%414% | 48+162%704% | 54*+114%996% | 36+97.9%1105% | 30−61.9%1516% | 18−22.4%761% | 25*−19.4%971% | 18—651% | 80—3602% | 24—960% | 31*—823% | |
| Operating income | −188—−436% | −55—−322% | −43—−314% | −42—−604% | −48*—−896% | −33—−1005% | −28—−1416% | −16—−661% | −22*—−871% | −16—−551% | −77—−3502% | −21—−860% | −27*—−723% | |
| Interest and finance income | — | — | — | 1.3+242%19.6% | 1.3*+134300%24.9% | 1.2+6739%37.4% | — | 0.4—16.2% | 0.0*−85.7%0.0% | 0.0—0.6% | — | — | 0.0*—0.2% | |
| Interest expense and finance costs | — | — | — | — | 0*−100%0.0% | — | — | — | 0.3*—10.8% | 0.3—10.7% | — | — | — | |
| Provision for credit losses | — | — | — | — | 0*—0.0% | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | −0.0—−0.0% | 0.1—0.4% | −0.0—−0.4% | −0.0−101%−0.0% | −0.0*—−0.7% | −1.2—−35.1% | −2.0—−97.8% | 0.4—16.2% | −0.3r−0.6*−4029%−10.7% | −0.0r−0.3—−1.6% | −0.6r−0.6—−27.4% | −0.6—−23.9% | 0.0*—0.2% | |
| Net income attributable to shareholders | −181—−420% | −53—−309% | −41—−299% | −40—−584% | −47*—−870% | −32—−973% | −28—−1415% | −17—−693% | −22*—−856% | −14—−504% | −79—−3568% | −15—−602% | −27*—−723% | |
| Earnings per share, basic | — | -2.89—— | -2.44—— | -2.93—— | — | -3.59—— | -3.86—— | -2.84—— | — | -22.68r-0.23—— | -1,920.85r-19.28—— | -535.72r-0.18—— | — | |
| Earnings per share, diluted | — | -2.89—— | -2.44—— | -2.93—— | — | -3.59—— | -3.86—— | -2.84—— | — | -22.68r-0.23—— | -1,920.85r-19.28—— | -535.72r-0.18—— | — | |
| Shares, weighted average (basic) | 18+107%— | 18+107%— | 17+127%— | 14+131%— | — | 8.9+1324%— | 7.3+17767%— | 5.9+21155%— | — | 0.6r62—— | 0.0r4.1—— | 0.0r81—— | — | |
| Shares, weighted average (diluted) | 18+107%— | 18+107%— | 17+127%— | 14+131%— | — | 8.9+1324%— | 7.3+17767%— | 5.9+21155%— | — | 0.6r62—— | 0.0r4.1—— | 0.0r81—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 163—67.2% | 163−14.3%67.2% | 176+40.6%69.4% | 185+40.8%71.9% | 208+110%74.9% | 190+573%75.3% | 125+2916%66.9% | 132+1769%68.3% | 99+296%60.6% | 28—29.7% | 4.2—5.9% | 7.0—5.2% | 25—16.2% | |
| Receivables | 15—6.0% | 15+319%6.0% | 12+409%4.6% | 8.8+166%3.4% | 6.3+70.3%2.3% | 3.5−13.3%1.4% | 2.3−30.5%1.2% | 3.3—1.7% | 3.7—2.3% | 4.0—4.2% | 3.3—4.7% | — | — | |
| Inventory | — | — | — | — | — | — | — | — | 8.4−38.4%5.2% | 7.9—8.3% | 9.5—13.5% | 12—9.1% | 14—8.8% | |
| Other current assets | 10—4.2% | 10+16.6%4.2% | 11+8.3%4.2% | 9.2+44.1%3.6% | 9.0+10.1%3.2% | 8.8+314%3.5% | 9.9+18.8%5.3% | 6.4−40.1%3.3% | 8.1+265%5.0% | 2.1—2.2% | 8.3—11.9% | 11—7.9% | 2.2—1.4% | |
| Current assets | 192—79.3% | 192−7.7%79.3% | 203+41.7%80.1% | 207+38.5%80.3% | 229+92.3%82.6% | 208+312%82.4% | 144+468%76.6% | 150+397%77.6% | 119+149%73.1% | 51—53.2% | 25—36.0% | 30—22.2% | 48—30.9% | |
| Property, plant and equipment | 45—18.5% | 45+5.4%18.5% | 45+5.7%17.6% | 45+7.5%17.4% | 44+5.2%16.0% | 43−0.4%16.9% | 42−2.1%22.6% | 42−55.1%21.7% | 42−55.1%25.9% | 43—45.0% | 43—61.5% | 93—68.8% | 94—60.9% | |
| Right-of-use (leased) assets | 1.2—0.5% | 1.2+232%0.5% | 1.3+207%0.5% | 1.4+188%0.6% | 1.5+173%0.6% | 0.4−40.1%0.1% | 0.4−36.7%0.2% | 0.5−33.8%0.3% | 0.6−31.4%0.3% | 0.6—0.7% | 0.7—1.0% | 0.8—0.6% | 0.8—0.5% | |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | 1.0—0.7% | 1.0—0.6% | |
| Other intangible assets | 0.1—0.0% | 0.10.0%0.0% | 0.10.0%0.0% | 0.10.0%0.0% | 0.10.0%0.0% | 0.10.0%0.0% | 0.10.0%0.1% | 0.1−98.7%0.1% | 0.1−98.8%0.1% | 0.1—0.1% | 0.1—0.2% | 9.5—7.0% | 9.7—6.3% | |
| Total assets | 242—100% | 242−4.0%100% | 254+35.6%100% | 258+33.7%100% | 277+70.2%100% | 252+166%100% | 187+166%100% | 193+42.5%100% | 163+5.5%100% | 95—100% | 70—100% | 135—100% | 154—100% | |
| Accounts payable | 17—7.0% | 17+99.8%7.0% | 9.1+16.3%3.6% | 9.6+130%3.7% | 8.1+78.5%2.9% | 8.5+117%3.4% | 7.8−25.2%4.2% | 4.2−36.9%2.2% | 4.5+20.2%2.8% | 3.9—4.1% | 10—14.8% | 6.6—4.9% | 3.8—2.4% | |
| Debt due within a year | — | — | — | — | — | — | — | — | 2.8+20.0%1.7% | 2.8—3.0% | 2.8—4.0% | 2.8—2.1% | 2.4—1.5% | |
| Current liabilities | 42—17.3% | 42+99.8%17.3% | 31+61.5%12.1% | 30+144%11.5% | 31+68.4%11.1% | 21+38.5%8.3% | 19−13.5%10.2% | 12−40.7%6.3% | 18−3.1%11.2% | 15—16.0% | 22—31.4% | 20—15.1% | 19—12.2% | |
| Long-term debt | — | — | — | — | — | — | — | — | 4.7−28.9%2.9% | 5.2—5.4% | 5.7—8.1% | 6.2—4.5% | 6.6—4.2% | |
| Lease liabilities (non-current) | 0.9—0.4% | 0.9+244%0.4% | 1.0+244%0.4% | 1.1+244%0.4% | 1.2+231%0.4% | 0.3−37.4%0.1% | 0.3−39.8%0.2% | 0.3−41.7%0.2% | 0.4−43.4%0.2% | 0.4—0.4% | 0.5—0.7% | 0.6—0.4% | 0.6—0.4% | |
| Total liabilities | 43—17.7% | 43+102%17.7% | 32+64.3%12.5% | 31+147%11.9% | 32+37.2%11.6% | 21+2.5%8.4% | 19−31.4%10.3% | 12−54.1%6.5% | 23−52.3%14.3% | 21—21.9% | 28—40.1% | 27—20.1% | 49—31.7% | |
| Retained earnings | −989—−408% | −989—−408% | −935—−368% | −895—−347% | −855—−308% | −808—−320% | −776—−414% | −748—−388% | −731—−449% | −709—−746% | −694—−988% | −616—−455% | −601—−389% | |
| Shareholders' equity | 199—82.3% | 199−13.7%82.3% | 222+32.3%87.5% | 227+25.9%88.1% | 245+75.7%88.4% | 231+211%91.6% | 168+299%89.7% | 180+66.8%93.5% | 140+32.3%85.7% | 74—78.1% | 42—59.9% | 108—79.9% | 106—68.3% | |
| Total liabilities and equity | 242—100% | 242−4.0%100% | 254+35.6%100% | 258+33.7%100% | 277+70.2%100% | 252+166%100% | 187+166%100% | 193+42.5%100% | 163+5.5%100% | 95—100% | 70—100% | 135—100% | 154—100% | |
| Shares outstanding | 19—— | 19+88.3%— | 17+123%— | 14+107%— | 13+192%— | 10−93.5%— | 7.5−23.3%— | 6.9−90.7%— | 4.4+20859%— | 156—— | 9.8—— | 74—— | 0.0r59—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 2.2+18.7%5.2% | 0.6+50.0%3.5% | 0.6+20.0%4.4% | 0.6+12.6%8.1% | 0.5*−1.6%9.1% | 0.4−20.0%12.2% | 0.5−44.4%25.0% | 0.5−59.3%20.3% | 0.5*−60.7%19.2% | 0.5—17.7% | 0.9—40.8% | 1.2—48.8% | 1.3*—33.4% | |
| Share-based compensation | 8.3+62.2%19.3% | 2.3*+19.2%13.3% | 2.3*+58.5%16.7% | 2.0+123%28.6% | 1.8*+100%33.2% | 1.9*+85.3%58.4% | 1.4*+23.3%71.2% | 0.9−47.9%36.3% | 0.9*−56.1%34.6% | 1.0*—36.8% | 1.2*—52.3% | 1.7—68.2% | 2.0*—53.9% | |
| Cash from operating activities | −165—−384% | −41*—−238% | −42*—−312% | −42—−615% | −40*—−736% | −29*—−875% | −15*—−742% | −17—−683% | −15*—−567% | −19*—−666% | −9.9*—−449% | −18—−708% | −22*—−591% | |
| Capital expenditure | −4.8—−11.0% | −0.6*—−3.5% | −0.6*—−4.3% | −1.7—−24.6% | −1.9*—−34.8% | −1.0*—−29.2% | −0.5*—−26.4% | −0.0—−0.2% | −0.0*—−0.1% | −0.0*—−0.3% | 0*—0.0% | −0.1—−4.4% | −0.4*—−11.6% | |
| Cash from investing activities | −3.9—−9.1% | −0.6*—−3.5% | −0.6*—−4.3% | −1.7—−24.6% | −1.0*—−18.9% | −1.0*—−29.2% | −2.5*—−127% | −0.0—−0.2% | −0.0*—−0.1% | −0.0*—−0.3% | 0*—0.0% | −0.1—−4.4% | −0.4*—−11.4% | |
| Debt repaid | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | −9.7—−397% | −0.7*—−27.3% | −0.7*—−25.0% | −0.7*—−31.9% | −0.2—−9.5% | — | |
| Shares issued | 149−42.1%345% | 28*−70.4%163% | 33*+141%247% | 20−67.7%293% | 67*−22.0%1242% | 95*+118%2883% | 14*—695% | 62—2562% | 86*+833%3325% | 44*—1545% | — | — | 9.2*—243% | |
| Shares bought back | — | — | — | — | −7.8*—−145% | 0*—0.0% | −2.9—−145% | −3.0—−125% | — | — | — | — | 0*—0.0% | |
| Cash from financing activities | 141−41.3%328% | 28*−70.2%164% | 34*+205%247% | 20−59.2%294% | 59*−30.5%1097% | 95*+121%2883% | 11*+56.5%550% | 50—2039% | 85*+109%3298% | 43*—1520% | 7.0*—318% | −0.2—−8.5% | 41*—1077% | |
| Exchange-rate effect on cash | −0.1−1757%−0.3% | −0.0*—−0.3% | −0.1*—−0.5% | 0.0—0.1% | −0.0*−158%−0.3% | −0.0*—−0.1% | −0.0*−500%−0.2% | −0.0—−0.4% | 0.0*—0.9% | −0.0*—−0.6% | 0.0*—0.0% | −0.0—−0.2% | −0.0*—−0.3% | |
| Change in cash | −28−117%−65.4% | −13*−121%−78.0% | −9.4*—−69.3% | −24−172%−346% | 18*−73.8%342% | 65*+170%1979% | −6.4*—−319% | 33—1356% | 71*+293%2732% | 24*—853% | −2.9*—−131% | −18—−721% | 18*—475% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Tonix Pharmaceuticals Holding Corp. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Zembrace Symtouch$9 M71%+8.9%
- Tosymra$2 M18%+53%
- Tonmya$1 M11%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Tonix Pharmaceuticals Holding Corp. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 7 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters2 offices5 subsidiaries | — |
| 🇮🇪 Ireland | 2 subsidiaries | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Tonix Pharmaceuticals Holding Corp.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Seth Lederman | $2.9 M | $4.6 M | $1.2 M | $0 |
| 2024Seth Lederman | $1.8 M | $1.1 M | $887 K | $0 |
| 2023Seth Lederman | $2.1 M | $647 K | $929 K | $1 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Tonix Pharmaceuticals Holding Corp.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Directors and officers 3 · Material agreement 2 · Shareholder vote 1 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Tonix Pharmaceuticals Holding Corp.#
$580 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues, pharmacy and defense.
- Health Issues13 reports
- Pharmacy8 reports
- Defense5 reports
- Disaster Planning/Emergencies4 reports
Lobbying firms hired in 2025
Burrell International Group LLC $160 K · VALCOUR LLC $120 K · Strategic Marketing Innovations $80 K · Broydrick & Associates $80 K · FOLEY HOAG LLP $80 K · Cardinal Point Partners $60 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $520 K | — | 17 |
| 2025 | $580 K | — | 25 |
| 2024 | $450 K | — | 16 |
| 2023 | $430 K | — | 16 |
| 2022 | $250 K | — | 14 |
| 2021 | $140 K | — | 12 |
| 2020 | $140 K | — | 13 |
| 2019 | $260 K | — | 15 |
| 2018 | $120 K | — | 14 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Tonix Pharmaceuticals”, “Tonix Pharmaceuticals, Inc.” and “Tonix Pharmaceuticals Holding Corp.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Tonix Pharmaceuticals Holding Corp.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $125 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Manager, Quality Control, Product Testing and ComplianceQuality Control Systems Managers | 1 | $125 K |
Where: Dracut, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $125 K | 1 |
| FY2024 | 1 | 1 | $125 K | 1 |
| FY2022 | 1 | 1 | $111 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Tonix Pharmaceuticals Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | 23 | · | · | · | · | · | · | · | 23 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 23 people | Restructuring planSEC 8-K | “(the “Company”) plans to reduce its workforce by 23 full-time employees and decommission its Advanced Development Center (“ADC”) in Massachusetts by June 7, 2024, to align the Comp…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Tonix Pharmaceuticals Holding Corp. compares in Biotechnology
- Market cap$111 M · higher than 38% of 726
- Revenue$13 M · higher than 46% of 647
- Net margin-946.0% · higher than 0% of 408
- Revenue growth29.9% · higher than 66% of 438
- Price / sales8.5× · lower than 47% of 339
- Price / book0.5× · lower than 93% of 534
- FCF yield-92.7% · higher than 11% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp.🇺🇸 | $111 M | — | -946.0% | +29.9% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 20, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia, Wikidata, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Tonix Pharmaceuticals Holding Corp.? Verify and update this profile — free
Show Tonix Pharmaceuticals Holding Corp.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.